NASDAQ:REPL Replimune Group Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.52 -0.11 (-0.59%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$17.55▼$18.9050-Day Range$13.32▼$18.6352-Week Range$13.05▼$40.22Volume737,381 shsAverage Volume352,838 shsMarket Capitalization$908.78 millionP/E RatioN/ADividend YieldN/APrice Target$47.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Stock Forecast (MarketRank)Overall MarketRank™2.48 out of 5 starsMedical Sector142nd out of 1,418 stocksBiological Products, Except Diagnostic Industry23rd out of 216 stocksAnalyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.57, Replimune Group has a forecasted upside of 156.9% from its current price of $18.52.Amount of Analyst CoverageReplimune Group has only been the subject of 4 research reports in the past 90 days. Previous Next 4.1 Community Rank Outperform VotesReplimune Group has received 142 “outperform” votes. (Add your “outperform” vote.)Underperform VotesReplimune Group has received 87 “underperform” votes. (Add your “underperform” vote.)Community SentimentReplimune Group has received 62.01% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Replimune Group and other stocks. Vote “Outperform” if you believe REPL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe REPL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $334,096.00 in company stock.Percentage Held by Insiders40.30% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.42% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($2.63) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -8.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -8.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Replimune Group (NASDAQ:REPL)Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More REPL Stock News HeadlinesJune 24, 2022 | americanbankingnews.comReplimune Group (NASDAQ:REPL) Shares Up 6.2%June 23, 2022 | americanbankingnews.comReplimune Group (NASDAQ:REPL) Shares Gap Up to $15.20June 5, 2022 | americanbankingnews.comReplimune Group (NASDAQ:REPL) Trading Up 6.7%June 3, 2022 | finance.yahoo.comReplimune Announces the Departure of Jason Rhodes from its Board of DirectorsJune 2, 2022 | finance.yahoo.comReplimune to Present at the Jefferies Healthcare ConferenceMay 30, 2022 | finance.yahoo.comIs There An Opportunity With Replimune Group, Inc.'s (NASDAQ:REPL) 38% Undervaluation?May 26, 2022 | finance.yahoo.comReplimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingMay 24, 2022 | markets.businessinsider.comAnalyst Ratings for Replimune GroupMay 19, 2022 | finance.yahoo.comReplimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate UpdateApril 14, 2022 | finance.yahoo.comWe Think Replimune Group (NASDAQ:REPL) Can Afford To Drive Business GrowthApril 8, 2022 | marketwatch.comNovavax Inc. stock outperforms market on strong trading dayApril 4, 2022 | benzinga.comJP Morgan Maintains Overweight on Replimune Group, Lowers Price Target to $39March 30, 2022 | finance.yahoo.comReplimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic ImmunotherapiesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPL CUSIPN/A CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees152Year FoundedN/ACompany Calendar Last Earnings5/19/2022Today6/24/2022Next Earnings (Estimated)8/05/2022Fiscal Year End3/31/2023Price Target and Rating Average Stock Price Forecast$47.57 High Stock Price Forecast$60.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+156.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.45% Return on Assets-23.92% Debt Debt-to-Equity Ratio0.06 Current Ratio19.46 Quick Ratio19.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.71 per share Price / Book2.13Miscellaneous Outstanding Shares49,070,000Free Float29,295,000Market Cap$908.78 million OptionableNot Optionable Beta2.30 Replimune Group Frequently Asked Questions Should I buy or sell Replimune Group stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Replimune Group stock. View analyst ratings for Replimune Group or view top-rated stocks. What is Replimune Group's stock price forecast for 2022? 7 brokers have issued 12-month price targets for Replimune Group's shares. Their REPL stock forecasts range from $30.00 to $60.00. On average, they expect Replimune Group's share price to reach $47.57 in the next twelve months. This suggests a possible upside of 156.9% from the stock's current price. View analysts' price targets for Replimune Group or view top-rated stocks among Wall Street analysts. How has Replimune Group's stock price performed in 2022? Replimune Group's stock was trading at $27.10 at the beginning of 2022. Since then, REPL shares have decreased by 31.7% and is now trading at $18.52. View the best growth stocks for 2022 here. When is Replimune Group's next earnings date? Replimune Group is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022. View our earnings forecast for Replimune Group. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) announced its quarterly earnings data on Thursday, May, 19th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.60). View Replimune Group's earnings history. Who are Replimune Group's key executives? Replimune Group's management team includes the following people: Mr. Philip Astley-Sparke FSA, CEO & Director (Age 51, Pay $759.52k)Dr. Robert Coffin Ph.D., Founder, Pres, Chief R&D Officer and Director (Age 57, Pay $759.52k)Ms. Tanya N. Lewis M.S., Chief Devel. Operations Officer (Age 51, Pay $16.23k)Ms. Jean M. Franchi, Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer (Age 56)Dr. Colin A. Love Ph.D., Chief Operating Officer (Age 64)Dr. Pamela Esposito Ph.D., Chief Bus. Officer (Age 47)Mr. Sushil Patel Ph.D., Chief Commercial Officer (Age 51) Who are some of Replimune Group's key competitors? Some companies that are related to Replimune Group include Abcam (ABCM), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), Bavarian Nordic A/S (BVNRY), Twist Bioscience (TWST), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Allogene Therapeutics (ALLO), Krystal Biotech (KRYS), ImmunityBio (IBRX), Iovance Biotherapeutics (IOVA), Exscientia (EXAI), Immunocore (IMCR) and Recursion Pharmaceuticals (RXRX). View all of REPL's competitors. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC). When did Replimune Group IPO? (REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What is Replimune Group's stock symbol? Replimune Group trades on the NASDAQ under the ticker symbol "REPL." Who are Replimune Group's major shareholders? Replimune Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include Omega Fund Management LLC (9.90%), BlackRock Inc. (4.52%), State Street Corp (3.63%), Vanguard Group Inc. (3.44%), Emerald Advisers LLC (2.40%) and Emerald Mutual Fund Advisers Trust (2.09%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin. View institutional ownership trends for Replimune Group. Which institutional investors are selling Replimune Group stock? REPL stock was sold by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, JPMorgan Chase & Co., Wellington Management Group LLP, Omega Fund Management LLC, Emerald Mutual Fund Advisers Trust, Citigroup Inc., Candriam Luxembourg S.C.A., and TD Asset Management Inc.. Company insiders that have sold Replimune Group company stock in the last two years include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke, and Robert Coffin. View insider buying and selling activity for Replimune Group or view top insider-selling stocks. Which institutional investors are buying Replimune Group stock? REPL stock was purchased by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., State Street Corp, Renaissance Technologies LLC, Emerald Advisers LLC, Federated Hermes Inc., Dimensional Fund Advisors LP, GSA Capital Partners LLP, and Vanguard Group Inc.. View insider buying and selling activity for Replimune Group or or view top insider-buying stocks. How do I buy shares of Replimune Group? Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Replimune Group's stock price today? One share of REPL stock can currently be purchased for approximately $18.52. How much money does Replimune Group make? Replimune Group (NASDAQ:REPL) has a market capitalization of $908.78 million. The company earns $-118.04 million in net income (profit) each year or ($2.26) on an earnings per share basis. How many employees does Replimune Group have? Replimune Group employs 152 workers across the globe. How can I contact Replimune Group? Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for Replimune Group is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at [email protected]. This page (NASDAQ:REPL) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
